Wegovy BMI requirements explained (NHS and private)

Ready to take the next step? See if you're eligible for expert-led weight loss support.

Check your eligibility

Curious about the Wegovy BMI requirements? Discover the BMI cutoff for access to Wegovy through the NHS or private care.



Curious about the Wegovy BMI requirements? Discover the BMI cutoff for access to Wegovy through the NHS or private care.

If you're thinking about starting weight loss treatment with Wegovy, one of the first things you'll need to check is whether you meet the BMI requirements.


Body mass index (BMI) is a simple calculation that uses your weight and height to estimate your body fat. It's far from perfect, but it's the most widely used tool for assessing eligibility for GLP-1 weight loss medication in both NHS and private care.

Here's what you need to know about Wegovy BMI requirements and how to get started safely.


NHS vs private: key differences in BMI cutoffs for treatment

Wegovy is available through both the NHS and private providers like SemaPen, but the BMI requirements aren't the same. Here's a quick breakdown.


BMI requirement Weight-related health condition is required Access pathway
NHS At least 35 (or 30–34.9 plus extra criteria) Yes GP first, then referral to a specialist
Private (e.g. SemaPen) At least 30 (or 27–29.9 with related health condition) Yes (if BMI 27-29.9) Private medical assessment

NHS access to Wegovy: stricter criteria and a slower process

Wegovy became available through the NHS UK for weight loss in September 2023, but GPs don't prescribe it directly. People must be referred to specialist weight management services to access Wegovy.

To qualify, patients generally need:

  • A BMI of 35 or more
  • A weight-related health condition, such as type 2 diabetes, high cholesterol or sleep apnoea
  • Documented attempts to lose weight through lifestyle changes
  • To be willing to follow a multidisciplinary weight-loss plan that includes diet and exercise

In some cases, people with a BMI between 30 and 34.9 may qualify if they have a significant obesity-related condition. A person's ethnic background may also be taken into account, since people from certain groups may experience health risks at a lower BMI.


The NHS criteria are designed to ensure that those at most risk receive support. But the process can be lengthy, and many people face long wait times for assessment and treatment.


Picture of hospital waiting room.

For full details, please see the official NHS guidance.

Private access: broader criteria and faster access to care

Private providers can prescribe Wegovy to a wider group of people. While the same medication is used, the process is more flexible and designed around your individual health status, not your local referral system.

You may be eligible for Wegovy privately if:

  • Your BMI is 30 or higher
  • Your BMI is between 27 and 29.9, and you have a related condition such as prediabetes, insulin resistance, high blood pressure or high cholesterol

As with the NHS criteria, a person's ethnic background is also considered.

At SemaPen, every patient completes a secure online health assessment reviewed by a licensed UK prescriber. If your BMI is in the lower range, your medical history will be evaluated to make sure semaglutide is safe and appropriate for you. This includes checking for medications that might interact and any conditions that could affect treatment.

There's no need for a GP referral. Instead, access is based on your needs and your eligibility.

SemaPen: your path to safe, supported weight loss

Do you meet the BMI criteria and want to explore semaglutide safely and effectively? Our team of obesity specialists is here to help. SemaPen's expert-led medical weight loss plans combine prescription access with remote monitoring, smart scales and compassionate support.

We make it easy to:

  • Check your eligibility quickly online
  • Get reviewed by a licensed UK prescriber
  • Access the right GLP-1 medication for you, whether that's Wegovy (semaglutide) or Mounjaro (tirzepatide)
  • Stay supported with regular check-ins and smart tracking

Are you ready to take the next step on your weight loss journey, with expert support focused on your goals? You can get started today by taking our online health assessment. Our specialists will review your answers and recommend a tailored treatment for you.

Sources

1. DHSC Media Team (2024) Accessing Wegovy for weight loss: Everything you need to know. GOV.UK. Retrieved from https://healthmedia.blog.gov.uk/2023/09/04/accessing-wegovy-for-weight-loss-everything-you-need-to-know/

This article was reviewed and approved by Alice Fletcher, Lead Bariatric Dietitian, on 31 July 2025.


  • Average 15-21% weight loss*
  • Tailored programmes built by real experts
  • Targeted support to make success feel simpler
  • Unique app with weight loss tools and lessons

Your journey starts here

Start your personalised weight loss plan in minutes.

1

Start your online consultation

2

Get approved by our clinical team

3

Begin your programme

Get started
While Wegovy and Mounjaro cause some muscle loss, there are as many myths as facts floating around.
by Simon Edward 25 May 2026
While Wegovy and Mounjaro cause some muscle loss, there are as many myths as facts floating around. Learn what one medical doctor has to say.
Discover what HDL cholesterol is, why it's considered 'good',
by Simon Edward 22 May 2026
Discover what HDL cholesterol is, why it's considered 'good', and how healthy lifestyle changes can support heart health.
How does metabolism influence weight loss? Learn about metabolic rate, calorie balance
by Simon Edward 18 May 2026
How does metabolism influence weight loss? Learn about metabolic rate, calorie balance and how to support your metabolism effectively.
Learn what foods to avoid and what to focus on with Mounjaro and Wegovy, including tips to support
by Simon Edward 15 May 2026
Learn what foods to avoid and what to focus on with Mounjaro and Wegovy, including tips to support safe, sustainable results.
The NHS has announced that 1.2 million more patients in England will be eligible for semaglutide
by Simon Edward 11 May 2026
The NHS has announced that 1.2 million more patients in England will be eligible for semaglutide by summer. Learn the facts behind the headline.
A new study suggests GLP-1 drugs like Mounjaro may improve asthma symptoms
by Simon Edward 8 May 2026
A new study suggests GLP-1 drugs like Mounjaro may improve asthma symptoms for those living with obesity. Join us as we unpack the results.
Wegovy patents are expiring in some parts of the world.
by Simon Edward 1 May 2026
Wegovy patents are expiring in some parts of the world. Does that mean we'll soon see cheaper generic versions in the UK?
In 2025, Novo Nordisk announced disappointing results from its semaglutide Alzheimer's trial.
by Simon Edward 1 May 2026
In 2025, Novo Nordisk announced disappointing results from its semaglutide Alzheimer's trial. But that's not the end of the story. Find out why.
Have you been told you're ineligible for weight loss drugs? Learn about your options and your rights
by Simon Edward 1 May 2026
Have you been told you're ineligible for weight loss drugs? Learn about your options and your rights, including asking for a second opinion on the NHS.
What's the safest way to dispose of weight loss pens and needles? Learn proper disposal methods
by Simon Edward 1 May 2026
What's the safest way to dispose of weight loss pens and needles? Learn proper disposal methods for Mounjaro and Wegovy in our UK guide.
More posts